MX2022010816A - Composiciones y métodos para evaluar la eficacia de los inhibidores de los transportadores de neurotransmisores. - Google Patents

Composiciones y métodos para evaluar la eficacia de los inhibidores de los transportadores de neurotransmisores.

Info

Publication number
MX2022010816A
MX2022010816A MX2022010816A MX2022010816A MX2022010816A MX 2022010816 A MX2022010816 A MX 2022010816A MX 2022010816 A MX2022010816 A MX 2022010816A MX 2022010816 A MX2022010816 A MX 2022010816A MX 2022010816 A MX2022010816 A MX 2022010816A
Authority
MX
Mexico
Prior art keywords
efficacy
inhibitors
methods
assessing
compositions
Prior art date
Application number
MX2022010816A
Other languages
English (en)
Spanish (es)
Inventor
Wen Luo
Hong Sun
John W Whitaker
Zafrin Dhali
Haiping Lu
Xiaojun Li
Wilson Wu
Original Assignee
Denovo Biopharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denovo Biopharma Llc filed Critical Denovo Biopharma Llc
Publication of MX2022010816A publication Critical patent/MX2022010816A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MX2022010816A 2020-03-06 2021-02-23 Composiciones y métodos para evaluar la eficacia de los inhibidores de los transportadores de neurotransmisores. MX2022010816A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062986603P 2020-03-06 2020-03-06
PCT/US2021/019265 WO2021178166A1 (en) 2020-03-06 2021-02-23 Compositions and methods for assessing the efficacy of inhibitors of neurotransmitter transporters

Publications (1)

Publication Number Publication Date
MX2022010816A true MX2022010816A (es) 2022-12-13

Family

ID=77613738

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010816A MX2022010816A (es) 2020-03-06 2021-02-23 Composiciones y métodos para evaluar la eficacia de los inhibidores de los transportadores de neurotransmisores.

Country Status (13)

Country Link
US (1) US12612661B2 (enExample)
EP (1) EP4106872B1 (enExample)
JP (1) JP2023515665A (enExample)
KR (1) KR20230005816A (enExample)
CN (1) CN115515680A (enExample)
AR (1) AR121515A1 (enExample)
AU (1) AU2021231683A1 (enExample)
BR (1) BR112022017770A2 (enExample)
CA (1) CA3174572A1 (enExample)
IL (1) IL296168A (enExample)
MX (1) MX2022010816A (enExample)
TW (1) TW202146660A (enExample)
WO (1) WO2021178166A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202000019303A1 (it) * 2020-08-05 2022-02-05 Univ Degli Studi Di Brescia Analoghi strutturali del metilfenidato come agenti disease-modifying della malattia di parkinson
CN114848835B (zh) * 2022-03-22 2023-08-25 暨南大学 塞来昔布的聚乙二醇修饰及连接叶酸基团的靶向药物分子及制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6945457B1 (en) * 1996-05-10 2005-09-20 Transaction Holdings Ltd. L.L.C. Automated transaction machine
JP4198582B2 (ja) * 2003-12-02 2008-12-17 独立行政法人科学技術振興機構 タンタルオキシナイトライド酸素還元電極触媒
WO2007128884A1 (en) * 2006-05-09 2007-11-15 Oy Jurilab Ltd Novel genes and markers in type 2 diabetes and obesity
US20080299125A1 (en) 2006-06-05 2008-12-04 Perlegen Sciences, Inc. Genetic basis of treatment response in depression patients
WO2008065544A2 (en) * 2006-09-11 2008-06-05 Mcgill University Genetic predictors of risk for type 2 diabetes mellitus
AU2008222563A1 (en) 2007-03-05 2008-09-12 Cancer Care Ontario Assessment of risk for colorectal cancer
US8355927B2 (en) 2010-11-05 2013-01-15 Genomind, Llc Neuropsychiatric test reports
US20170029892A1 (en) * 2009-05-29 2017-02-02 Jay L. Lombard Methods and compositions for the treatment of post-traumatic stress disorder
MX2013008846A (es) 2011-01-31 2014-02-11 Denovo Biomarkers Inc Metodo para descubrir biomarcadores farmacogenomicos.
WO2012156515A1 (en) * 2011-05-18 2012-11-22 Rheinische Friedrich-Wilhelms-Universität Bonn Molecular analysis of acute myeloid leukemia
US10202652B2 (en) 2011-06-08 2019-02-12 Denovo Biopharma (Hangzhou) Ltd. Co. Methods and compositions of predicting activity of retinoid X receptor modulator
US20140274764A1 (en) 2013-03-15 2014-09-18 Pathway Genomics Corporation Method and system to predict response to treatments for mental disorders
US20170253928A1 (en) * 2013-03-15 2017-09-07 Pathway Genomics Corporation Method and system to predict response to treatments for mental disorders
PL3117012T5 (pl) * 2014-03-14 2026-03-16 Caredx, Inc. Sposoby monitorowania terapii immunosupresyjnych u biorcy przeszczepu

Also Published As

Publication number Publication date
EP4106872A1 (en) 2022-12-28
US20230193388A1 (en) 2023-06-22
BR112022017770A2 (pt) 2022-11-29
IL296168A (en) 2022-11-01
JP2023515665A (ja) 2023-04-13
AU2021231683A1 (en) 2022-09-22
TW202146660A (zh) 2021-12-16
AR121515A1 (es) 2022-06-08
KR20230005816A (ko) 2023-01-10
EP4106872B1 (en) 2026-07-15
CN115515680A (zh) 2022-12-23
CA3174572A1 (en) 2021-09-10
WO2021178166A1 (en) 2021-09-10
US12612661B2 (en) 2026-04-28
EP4106872A4 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
Sujana et al. Whistleblowing system, competence, morality, and internal control system against fraud prevention on village financial management in Denpasar
WO2020243415A3 (en) Tead inhibitors and uses thereof
EP4357783A3 (en) Highly sensitive system and methods for analysis of troponin
MX2023012080A (es) Composiciones de acido ribonucleico interferente (arni) de transtiretina (ttr) y sus usos en el tratamiento o prevencion de enfermedades asociadas con transtiretina (ttr).
BR112023021561A2 (pt) Compostos de carbóxi-benzimidazol moduladores de glp-1r
BR112021015056A2 (pt) Inibidores específicos de complexos ltbp de tgf-beta e usos dos mesmos
MX2023013173A (es) Degradadores de cinasa 2 dependiente de ciclina (cdk2) y sus usos.
MY167390A (en) Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
PH12021500008A1 (en) Transglutaminase 2 (tg2) inhibitors
WO2009029550A3 (en) Highly sensitive system and methods for analysis of prostate specific antigen (psa)
BR112022005711A2 (pt) Métodos e composições para tratar uma doença ou transtorno
WO2020239895A3 (en) Detection of colorectal cancer
PH12016500302A1 (en) Compositions and method for treating complement-associated conditions
GT201000088A (es) 2 -fluoro-2´desoxitetrahidrouridinas como inhibidores de citidina desaminasa
BR112019002679A2 (pt) redução de sinal de ácidos nucleicos contaminantes
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
MX2024004993A (es) Agentes degradantes de la proteina tirosina cinasa 2 (tyk2) y usos de los mismos.
WO2021092145A8 (en) Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
FR3045834B1 (fr) Diluant de reactifs pour immunoessai
WO2022204581A3 (en) Tgf-beta inhibitors and use thereof
MX2026002406A (es) Degradadores del transductor de señales y activador de la transcripción 6 (stat6) y usos de los mismos
WO2007100777A3 (en) Methods for the treatment of adhd and related disorders
BR112012021411A2 (pt) mutações braf que conferem resistência a inibidores braf.
AR121515A1 (es) Composiciones y métodos para evaluar la eficacia de inhibidores de transportadores de neurotransmisores
ZA202303864B (en) Microbiome signature for the charcatrization of skin types